Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Vip Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$2,550,013

1,181 payments

Through program year 2025, Vip Trials LLC is reported as receiving $2,550,013 in research payments, across 1,181 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $481,372 10
2024 Research $919,318 61
2023 Research $201,616 45
2022 Research $532,498 407
2021 Research $353,136 602
2020 Research $62,073 56

Breakdown

Who paid Research payments · program years 2020–2025
  1. Eli Lilly and Company $1,418,894 32 payments
  2. Novo Nordisk AS $379,726 817 payments
  3. Alnylam Pharmaceuticals Inc. $340,545 128 payments
  4. Biohaven Pharmaceutical Holding Company Ltd. $152,716 12 payments
  5. Pfizer Inc. $102,796 28 payments
  6. Esperion Therapeutics, Inc. $92,188 149 payments
  7. AbbVie, Inc. $32,418 9 payments
  8. Biohaven Pharmaceuticals, Inc. $30,730 6 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight and Type 2 Diabetes (Attain-2) $917,009 8 payments
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $296,281 9 payments
  3. A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) $292,919 120 payments
  4. A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $157,644 8 payments
  5. Nn9924-4635 $147,291 98 payments
  6. A Phase 4 Open-Label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention $138,586 9 payments
  7. Nn9535-4352 $112,985 190 payments
  8. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $92,188 149 payments
  9. A Phase 2B Multicenter Randomized Doubleblind Placebocontrolled Doseranging Study to Evaluate the Efficacy Safety and Pharmacokinetics of Pf06480605 in Adult Participants With Moderate to Severe Ulcerative Colitis $77,722 21 payments
  10. Ex9536-4388 $77,001 132 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record